UK patient registry to continue for fourth year with key changes

Drug Science has announced that its cannabis patient registry, Project Twenty21, will continue collecting data for a fourth year with new partners on board.

The UK charity for drug reform confirmed this week that its medicinal cannabis patient registry, formerly known as Project Twenty21, will continue collecting data for the foreseeable future. 

Now operating as T21, the project was launched in November 2019 to help build the UK evidence base for the safety and efficacy of cannabis medicines.

Following the completion of the initial phase of the study, the registry now has over 3,500 patients enrolled and has published a number of findings from the data, including how cannabis medicines can support a better quality of life, sleep, mood, reduced pain, PTSD and anxiety.

According to an announcement on the Drug Science website, T21 will now be supported by founding partners Khiron Life Sciences Corp, Leva (formerly Cellen Health) and JMCC Group, with Canopy Growth (under the Spectrum Therapeutical brand) and Ethypharm also joining the project.

In the statement, Drug Science said: “Each partner enables T21 to offer its new range of discounted medical cannabis products, and we are grateful for their essential support. 

“Thanks to the involvement of all our legacy partners, we have now collected a significant amount of real-world evidence from approximately 3,500 patients, which is enhancing our understanding of the effectiveness of CBPMs in a range of conditions.

“Step by step, these facts are how we can make whole-plant cannabis an affordable, available medicine in the UK. And Drug Science will continue to publish our T21 research for as long as we are able or needed to.”

Lyphe Group, another of the original partners, is not currently taking on any new T21 patients, but was unable to comment on any further developments at the time of publication.

What products will now be available on T21? 

The new T21 formulary will contain a variety of cannabis-based medicinal products, including different THC/CBD ratios of both dried cannabis flowers and oils. 

New products are expected to be introduced in the coming months. 

What impact will the changes have on prices?

T21 says it is committed to continuing ​​its mission to grant eligible patients access to cannabis treatment at a discounted price; however, the prices of products on the formulary will now be determined by the producers.

Khiron Life Sciences Corp, Leva and JMCC Group have confirmed that they will not change their existing pricing.

What impact will all this have on the data collection? 

Drug Science says that the change of partners will not impact the data collection. 

While a clinic may not be taking on any new T21 patients, it will continue to collect data from existing patients regardless of whether the products they are prescribed are listed on the T21 formulary. 

You can find more information about T21 on the Drug Science website.

• Is cannabis more effective at improving mood than antidepressants?
• MyAccess Clinics rejoins Project Twenty21 to help build real-world data
• Germany’s official plans for cannabis legalisation a ‘victory’ for consumers
• Sana Healthcare to launch UK’s first condition-specific cannabis formulary
• Europe’s largest patient registry expands to offer more affordable access